Publications by Anne Mobergslien
19 publications found
Original articles
Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model
Front Med (Lausanne), 9, 1033303
DOI 10.3389/fmed.2022.1033303, PubMed 36457578
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
J Immunother Cancer, 9 (10)
DOI 10.1136/jitc-2021-002387, PubMed 34615703
Exploring 5'-Biotinylation of the Sense Strand to Improve siRNA Specificity and Potency
Methods Mol Biol, 2115, 163-170
DOI 10.1007/978-1-0716-0290-4_9, PubMed 32006400
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
Clin Cancer Res, 25 (15), 4723-4734
DOI 10.1158/1078-0432.CCR-18-3476, PubMed 31064781
Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
Oncotarget, 7 (46), 75940-75953
DOI 10.18632/oncotarget.12445, PubMed 27713158
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Case Rep Med, 2016, 9639585
DOI 10.1155/2016/9639585, PubMed 27504122
Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells
Mol Ther Methods Clin Dev, 2, 15043
DOI 10.1038/mtm.2015.43, PubMed 26605373
A facile method for interfering with off-target silencing mediated by the sense strand
Methods Mol Biol, 1218, 293-300
DOI 10.1007/978-1-4939-1538-5_18, PubMed 25319659
Recombinant Lactobacillus plantarum induces immune responses to cancer testis antigen NY-ESO-1 and maturation of dendritic cells
Hum Vaccin Immunother, 11 (11), 2664-73
DOI 10.1080/21645515.2015.1056952, PubMed 26185907
Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses
Methods Mol Biol, 1218, 269-76
DOI 10.1007/978-1-4939-1538-5_16, PubMed 25319657
Exosome-derived miRNAs and cellular miRNAs activate innate immunity
J Innate Immun, 6 (1), 105-10
DOI 10.1159/000351460, PubMed 23774807
A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells
FASEB J, 27 (8), 3272-83
DOI 10.1096/fj.12-224758, PubMed 23671272
Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients
Int J Oncol, 43 (1), 280-8
DOI 10.3892/ijo.2013.1922, PubMed 23620105
Selective killing of cancer cells by peptide-targeted delivery of an anti-microbial peptide
Biochem Pharmacol, 84 (9), 1123-32
DOI 10.1016/j.bcp.2012.08.002, PubMed 22922046
Efficient siRNA targeted delivery into cancer cells by gastrin-releasing peptides
Bioconjug Chem, 23 (5), 1040-9
DOI 10.1021/bc300050j, PubMed 22443209
Galectin-1 and -3 gene silencing in immature and mature dendritic cells enhances T cell activation and interferon-γ production
J Leukoc Biol, 91 (3), 461-7
DOI 10.1189/jlb.0711361, PubMed 22167721
Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins
Int J Oncol, 38 (2), 385-90
DOI 10.3892/ijo.2010.869, PubMed 21165555
Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation
Scand J Immunol, 71 (4), 267-74
DOI 10.1111/j.1365-3083.2010.02378.x, PubMed 20384870
Optimized protocols for siRNA delivery into monocytes and dendritic cells
Methods Mol Biol, 629, 71-85
DOI 10.1007/978-1-60761-657-3_5, PubMed 20387143